PMID- 29877921
OWN - NLM
STAT- MEDLINE
DCOM- 20191115
LR  - 20191115
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 43
IP  - 1
DP  - 2019 Jan
TI  - ALK Expression in Angiomatoid Fibrous Histiocytoma: A Potential Diagnostic 
      Pitfall.
PG  - 93-101
LID - 10.1097/PAS.0000000000001103 [doi]
AB  - We recently encountered a case of primary pulmonary angiomatoid fibrous 
      histiocytoma (AFH), which was initially misdiagnosed as inflammatory 
      myofibroblastic tumor (IMT) based in part on anaplastic lymphoma kinase (ALK) 
      expression by immunohistochemistry (IHC). Prompted by this experience, we 
      evaluated ALK expression in 11 AFH, 15 IMT, and 11 follicular dendritic cell 
      sarcomas using 3 different antibody clones: D5F3, 5A4, and ALK1. ALK IHC positive 
      cases were analyzed with fluorescence in situ hybridization (FISH) using dual 
      color ALK break-apart probe kit. The majority of AFH cases studied were positive 
      for ALK IHC with at least 1 antibody (9/11 D5F3, 6/9 5A4, 1/9 ALK1), most 
      demonstrating moderate to strong cytoplasmic staining. AFH with positive ALK IHC 
      showed no ALK gene rearrangement by FISH (0/8) with ALK copy number ranging from 
      1.6 to 2.1. Sixty-seven percent of IMT were ALK positive by IHC (10/15 D5F3, 8/15 
      5A4, 7/15 ALK1), and 9 of the 10 cases were positive for ALK gene rearrangement 
      by FISH. All follicular dendritic cell sarcomas were negative for ALK by IHC 
      (D5F3 and 5A4). Our results indicate that ALK expression in AFH is common, 
      particularly with the highly sensitive D5F3 and 5A4 antibodies and enhanced 
      detection systems, and may be a potential source of diagnostic confusion with 
      IMT. The underlying mechanism of ALK expression in AFH is unclear, although it 
      does not appear to be from ALK rearrangement or amplification.
FAU - Cheah, Alison L
AU  - Cheah AL
AD  - Department of Histopathology, Douglass Hanly Moir Pathology, Macquarie Park, NSW, 
      Australia.
FAU - Zou, Youran
AU  - Zou Y
AD  - Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory 
      Medicine.
FAU - Lanigan, Christopher
AU  - Lanigan C
AD  - Core Research Group, Cleveland Clinic, Cleveland, OH.
FAU - Billings, Steven D
AU  - Billings SD
AD  - Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory 
      Medicine.
FAU - Rubin, Brian P
AU  - Rubin BP
AD  - Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory 
      Medicine.
FAU - Hornick, Jason L
AU  - Hornick JL
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA.
FAU - Goldblum, John R
AU  - Goldblum JR
AD  - Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory 
      Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - Histiocytoma, Angiomatoid Fibrous
SB  - IM
CIN - Am J Surg Pathol. 2019 Aug;43(8):1156. PMID: 31021856
MH  - Anaplastic Lymphoma Kinase/analysis/*biosynthesis/genetics
MH  - Biomarkers, Tumor/*analysis
MH  - Diagnosis, Differential
MH  - Gene Rearrangement
MH  - Histiocytoma, Malignant Fibrous/*diagnosis/genetics
MH  - Humans
MH  - Lung Neoplasms/diagnosis/genetics
MH  - Myofibroma/*diagnosis/genetics
EDAT- 2018/06/08 06:00
MHDA- 2019/11/16 06:00
CRDT- 2018/06/08 06:00
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2019/11/16 06:00 [medline]
PHST- 2018/06/08 06:00 [entrez]
AID - 10.1097/PAS.0000000000001103 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2019 Jan;43(1):93-101. doi: 10.1097/PAS.0000000000001103.